Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib-R-CAP vs R-CHOP in Young DLBCL Patients with Poor IPI
NCT01848132Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Oct 2013
- Primary completion
- Jan 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of bortezomib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by GELTAMO. Primary endpoint: Event-Free Survival at 2 years. Started Oct 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01848132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01848132.